What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Pancreatic cancer, Oncology, Cancer and Prospective cohort study.
His research is interdisciplinary, bridging the disciplines of Endocrinology and Internal medicine.
His Pancreatic cancer research incorporates themes from Odds ratio, Precision medicine, Cancer research, Case-control study and Pancreas.
His Odds ratio study combines topics from a wide range of disciplines, such as Gastroenterology, Genetics and Genome-wide association study.
His biological study spans a wide range of topics, including Malignancy, Irinotecan, Oxaliplatin, Colorectal cancer and Radiation therapy.
The various areas that Brian M. Wolpin examines in his Prospective cohort study study include Spearman's rank correlation coefficient, Chromatography, Metabolomics and Metabolite.
His most cited work include:
- Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer (463 citations)
- A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 (456 citations)
- Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology (453 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Pancreatic cancer, Oncology, Cancer and Cancer research.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Endocrinology.
The study incorporates disciplines such as Odds ratio, Genome-wide association study, Single-nucleotide polymorphism, Case-control study and Adenocarcinoma in addition to Pancreatic cancer.
As part of the same scientific family, Brian M. Wolpin usually focuses on Oncology, concentrating on Irinotecan and intersecting with Oxaliplatin.
His Cancer study which covers Risk factor that intersects with Relative risk and Pancreatic disease.
His work investigates the relationship between Cancer research and topics such as Phenotype that intersect with problems in Cell.
He most often published in these fields:
- Internal medicine (65.25%)
- Pancreatic cancer (54.43%)
- Oncology (39.67%)
What were the highlights of his more recent work (between 2019-2021)?
- Pancreatic cancer (54.43%)
- Internal medicine (65.25%)
- Cancer research (22.62%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Pancreatic cancer, Internal medicine, Cancer research, Oncology and Cancer.
Pancreatic cancer is a subfield of Genetics that he tackles.
His Gastroenterology research extends to Internal medicine, which is thematically connected.
Brian M. Wolpin has researched Cancer research in several fields, including Phenotype, Carcinogenesis, Tumor microenvironment, Immune system and Organoid.
His Oncology research includes themes of Genetic counseling, Prospective cohort study, Borderline resectable and Germline.
Brian M. Wolpin interconnects Immunofluorescence and Biomarker in the investigation of issues within Cancer.
Between 2019 and 2021, his most popular works were:
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial (44 citations)
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. (33 citations)
- Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. (22 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Brian M. Wolpin mainly focuses on Pancreatic cancer, Internal medicine, Oncology, Disease and Cancer.
Brian M. Wolpin has included themes like Tumor microenvironment, Cancer research, Flow cytometry and Circulating biomarkers in his Pancreatic cancer study.
His Internal medicine research is multidisciplinary, incorporating elements of Diabetes mellitus and Gastroenterology.
His work carried out in the field of Oncology brings together such families of science as Neoadjuvant therapy, Borderline resectable, Chemotherapy and Adenocarcinoma.
The various areas that Brian M. Wolpin examines in his Disease study include Incidence and MEDLINE.
His study in Cancer is interdisciplinary in nature, drawing from both Heritability, Relative risk, Genetic predisposition and Medical genetics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
